Logo

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center. The results, published in Cancer Discovery, prime the combination strategy for future clinical trials.

👉 Full Story